Pasithea Therapeutics Acquires AlloMek Therapeutics
October 12, 2022 08:00 ET
|
Pasithea
-- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application with the FDA to Enter the Clinic in 2H 2023 -- Plans to...
Pasithea Therapeutics to Call Special Meeting of Stockholders
October 03, 2022 18:03 ET
|
Pasithea
MIAMI BEACH, Fla., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors
September 20, 2022 08:00 ET
|
Pasithea
MIAMI BEACH, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and...
Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz
September 15, 2022 08:00 ET
|
Pasithea
-- Dr. Cudkowicz is a pioneer in the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases -- MIAMI BEACH, Fla., Sept. 15, 2022 (GLOBE NEWSWIRE) --...
Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 09, 2022 10:32 ET
|
Pasithea
MIAMI BEACH, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new...
Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference
August 18, 2022 08:00 ET
|
Pasithea
-- Annual “From Laboratory to Clinic” conference, held at Trinity College, Oxford University, explores latest discoveries in immunology and molecular medicine ---- PAS002 is a proprietary DNA vaccine...
Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis
August 11, 2022 08:00 ET
|
Pasithea
-- PAS002 is a proprietary DNA tolerizing vaccine construct encoding GlialCAM ---- PAS002 effectively reduces disease severity, delays onset of illness, while also reducing relapse severity ----...
Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Group’s Unjustified Campaign
August 02, 2022 07:00 ET
|
Pasithea
Stockholders Should Protect Upside in Potential Groundbreaking Therapies for MS, ALS and Other Large Unmet Medical Conditions from Activist’s Apparent Cash Grab Board Unanimously Recommends...
Pasithea Therapeutics Awarded a Drug Development Research Grant
July 14, 2022 08:00 ET
|
Pasithea
-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction ---- Provides approximately U.S. $694,000 of non-dilutive funding -- MIAMI BEACH, Fla., July 14, 2022 ...
Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond
June 23, 2022 08:00 ET
|
Pasithea
MIAMI BEACH, Fla., June 23, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of...